BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16914568)

  • 1. CHEK2-positive breast cancers in young Polish women.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
    Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
    Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
    Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology of breast cancer in women with constitutional CHEK2 mutations.
    Huzarski T; Cybulski C; Domagała W; Gronwald J; Byrski T; Szwiec M; Woyke S; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2005 Mar; 90(2):187-9. PubMed ID: 15803365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer predisposing alleles in Poland.
    Górski B; Cybulski C; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Stawicka M; Gozdecka-Grodecka S; Szwiec M; Urbański K; Mituś J; Marczyk E; Dziuba J; Wandzel P; Surdyka D; Haus O; Janiszewska H; Debniak T; Tołoczko-Grabarek A; Medrek K; Masojć B; Mierzejewski M; Kowalska E; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2005 Jul; 92(1):19-24. PubMed ID: 15980987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.
    Zhang S; Phelan CM; Zhang P; Rousseau F; Ghadirian P; Robidoux A; Foulkes W; Hamel N; McCready D; Trudeau M; Lynch H; Horsman D; De Matsuda ML; Aziz Z; Gomes M; Costa MM; Liede A; Poll A; Sun P; Narod SA
    Cancer Res; 2008 Apr; 68(7):2154-7. PubMed ID: 18381420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A-positive breast cancers in young women from Poland.
    Debniak T; Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Jul; 103(3):355-9. PubMed ID: 17061045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors.
    Szymanska-Pasternak J; Szymanska A; Medrek K; Imyanitov EN; Cybulski C; Gorski B; Magnowski P; Dziuba I; Gugala K; Debniak B; Gozdz S; Sokolenko AP; Krylova NY; Lobeiko OS; Narod SA; Lubinski J
    Gynecol Oncol; 2006 Sep; 102(3):429-31. PubMed ID: 16828850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
    Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
    Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
    Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
    Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
    Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
    Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
    Serrano-Fernández P; Debniak T; Górski B; Bogdanova N; Dörk T; Cybulski C; Huzarski T; Byrski T; Gronwald J; Wokołorczyk D; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2009 Sep; 117(1):161-5. PubMed ID: 19030985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.